Chromatin-to-nucleoprotamine transition is controlled by the histone H2B variant, TH2BEmilie Montellier1, Fayçal Boussouar1, Sophie Rousseaux1, Kai Zhang2, Thierry Buchou1, François Fenaille3, Hitoshi Shiota1, Alexandra Debernardi1, Patrick Héry4, Sandrine Curtet1, Mahya Jamshidikia1, Sophie Barral1, Hélène Holota5, Aurélie Bergon5, Fabrice Lopez5, Philippe Guardiola6, Karin Pernet7, Jean Imbert5, Carlo Petosa8, Minjia Tan9,10, Yingming Zhao9,10, Matthieu Gérard4, Saadi Khochbin1*1 - INSERM, U823; Université Joseph Fourier - Grenoble 1; Institut Albert Bonniot, Grenoble, F-38700 France
2 - State Key Laboratory of Medicinal Chemical Biology & Department of Chemistry, Nankai University, Tianjin 300071, China
3 – Laboratoire d'Etude du Métabolisme des Médicaments, DSV / iBiTec-S / SPI, CEA Saclay, 91191 Gif sur Yvette, Cedex, France
4 - CEA, iBiTec-S, Gif-sur-Yvette, F-91191 France
5 - INSERM UMR_S 1090; TGML/TAGC, Aix-Marseille Université, Marseille, France
6 - INSERM, U892; Centre de Recherche sur le Cancer Nantes Angers et UMR_S 892; Université d’Angers; Plateforme SNP, Transcriptome & Epigénomique; Centre Hospitalier Universitaire d’Angers; Angers, F-49000 France
7 - INSERM U836; Université Joseph Fourier, Grenoble Institute of Neuroscience, Grenoble, F-38700 France,
8 – Univ. Grenoble Alpes / CNRS / CEA, Institut de Biologie Structurale, 38027 Grenoble, France.
9 - Ben May Department of Cancer Research, The University of Chicago, Chicago, IL 60637, USA
10 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, P.R. China
Genes and development, 24 juillet 2013 Doi: 10.1101/gad.220095.113